AstraZeneca PLC is 247.1x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($286.27 B vs $1.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | XERS | AZN |
|---|---|---|
| Market cap | $1.16 B | $286.27 B |
| US-listed rank | #2528 | #45 |
| Revenue (latest FY) | $291.85M | - |
| Net income (latest FY) | $554.00K | - |
| Net margin | 0.2% | - |
| P/E (trailing FY) | 2091.0 | - |
| SEC filings | 290 | 1,004 |
AstraZeneca PLC is 247.1x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($286.27 B vs $1.16 B).
Full pages: Xeris Biopharma Holdings, Inc. and AstraZeneca PLC, or browse the full rankings.